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http://dx.doi.org/10.1016/j.ccr.2013.04.019SUMMARYThe incidence of cholangiocellular carcinoma (CCC) is increasing worldwide. Using a transgenic mouse
model, we found that expression of the intracellular domain of Notch 1 (NICD) in mouse livers results in the
formation of intrahepatic CCCs. These tumors display features of bipotential hepatic progenitor cells, indi-
cating that intrahepaticCCCcan originate from this cell type.We show that human andmouseCCCsare char-
acterized by high expression of the cyclin E protein and identified the cyclin E gene as a direct transcriptional
target of the Notch signaling pathway. Intriguingly, blocking g-secretase activity in human CCC xenotrans-
plants results in downregulation of cyclin E expression, induction of apoptosis, and tumor remission in vivo.INTRODUCTION
Cholangiocellular carcinoma (CCC) is a primary liver cancer with
biliary differentiation (Patel, 2006). Several recent studies
describe a significant increase in the incidence of this tumor in
Europe and the United States; the reasons for this increase are
not understood (El-Serag et al., 2009; von Hahn et al., 2011;
West et al., 2006). Even though CCC accounts for up to 15%
of all liver cancers, the molecular alterations that lead to this
disease are mostly unknown. Predisposing conditions such as
primary sclerosing cholangitis, chronic infection with liver flukes,
or biliary stones led to the hypothesis that chronic inflammation
of the biliary epithelium might be a prerequisite for the formation
of CCC. However, no uniform genetic alteration has been identi-
fied that is responsible for the formation of CCC. In addition, only
very few mouse models of CCC are currently available. Recently
Xu and colleagues showed that liver-specific disruption of the
SMAD4 and PTEN genes leads to the formation of CCC (Xu
et al., 2006). NF2 knockout mice were shown to develop hepato-Significance
Overactivation of the Notch signaling pathway leads to a dysreg
CCC. Inhibition of Notch activity in CCC blocks tumor cell prolif
shed light on the pathogenesis of CCC and pinpoint Notch inh
784 Cancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc.cellular carcinomas and CCCs from a common progenitor cell
(Benhamouche et al., 2010), supporting the hypothesis that
CCC may arise from undifferentiated hepatic precursor cells.
A number of studies showed that the Notch signaling pathway
is of central importance for embryonic development of the biliary
tree. For example, loss of the Notch ligand jagged1 or the Notch
2 gene results in congenital hypoplasia of the biliary system,
called the Alagille syndrome (Geisler et al., 2008; Lorent et al.,
2004; Ryan et al., 2008). Analysis of mice after liver-specific inac-
tivation of RBP-Jk, a common transcriptional mediator of Notch
signaling, revealed a reduced number of biliary cells differenti-
ating from hepatoblasts (Zong et al., 2009). Notch levels are
regulated by ubiquitylation-dependent protein turnover, which
is controlled by the SCFFbw7 E3-ubiquitin ligase (Welcker and
Clurman, 2008). The F-Box component of this E3-ligase, the
Fbw7 protein, was found to be frequently mutated in human
CCC (Akhoondi et al., 2007). However, it is unknown whether
Notch dysregulation is involved in the initiation and progression
of CCC.ulation of the oncogene cyclin E, resulting in the formation of
eration and induces apoptosis in vitro and in vivo. Our results
ibition as a promising treatment option.
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Figure 1. NotchIC::AlbCre Mice Show Reduced Body and Liver Weights
(A–C) Analysis of liver and body weight and liver-to-body weight ratio of theNotchIC::AlbCremice compared to littermates (A and B: 10 weeks of age; C: 6 weeks
of age).
(D) Hematoxylin and eosin (H&E) stained liver sections ofNotchIC::AlbCremice. Immunohistochemical staining ofNotchIC::AlbCre livers using antibodies against
Hes1 (103 and 603 magnification) and NICD in 6-week-old mice.
(E) Western blot analysis of liver tissue from twoNotchIC::AlbCre mice and two wild-type littermates using an antibody against HES1, a downstream target of the
Notch pathway in 6-week-old mice. Scale bars represent mean values ± SEM. *p < 0.05; **p < 0.001.
See also Figure S1.
Cancer Cell
Notch Induces Cholangiocellular CarcinomaIn this study, we set out to explore the function of Notch
signaling in the formation of liver cancers. We used a transgenic
mouse line that allows the liver-specific expression of the intra-
cellular domain of Notch receptor 1 (NICD).
RESULTS
Expression of Notch ICD in Mouse Liver Interferes with
Hepatocyte Proliferation
To directly test the consequences of constitutive Notch expres-
sion in liver tissue, we crossed a transgenic mouse line that
allows for tissue-specific overexpression of the intracellulardomain of Notch 1 (Rosa26Notch1IC) (Murtaugh et al., 2003) to
a mouse line that expresses cre-recombinase under the control
of the albumin regulatory elements and the alpha-fetoprotein
enhancers (AlbCre) (Kellendonk et al., 2000). Use of this cre-
line results in the expression of NICD in the vast majority of
all hepatocytes and biliary epithelial cells during the forma-
tion of the second ductal layer (E16.5) (Zong et al., 2009).
NotchIC::AlbCre mice were born at normal Mendelian ratios,
but showed proportionally reduced body and liver weights (Fig-
ures 1A–1C) and up to 25% reduced body size (Figure S1A [age,
7 months] available online) compared to wild-type control litter-
mates. To show liver-specific activation of the NICD transgene,Cancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc. 785
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Figure 2. Notch Signaling Leads to Dysregulated Expression of Cyclin E and Genetic Instability
(A) b-catenin staining (for the detection of cell size) was performed on liver sections from wild-type and NotchIC::AlbCre mice at 12 weeks of age.
(B) Quantification of cell size in the indicatedmouse strains was done after b-catenin staining to visualize the cell surface at 12 weeks of age. Five hundred cells on
average were analyzed using a photometric system.
(C) Three hundred visual fields were counted on average to determine the number of hepatocytes in the livers of the indicated mouse strains at the age of
12 weeks.
(D) The DNA content of hepatocytes of the indicated mouse strains was determined by microphotometry analysis of Feulgen-stained liver sections at the age of
11 weeks.
(E and F) Quantification of the number of BrdU and phospho-Histone-H3-positive hepatocytes after induction of liver regeneration in wild-type and
NotchIC::AlbCre double transgenicmice at the age of 10weeks. For BrdU staining, an average of 900–2000 cells, and for HH3 staining at least 700 cells from up to
(legend continued on next page)
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Cancer Cell
Notch Induces Cholangiocellular Carcinomawe prepared extracts from different mouse tissues and deter-
mined the expression of the green fluorescent (GFP) protein,
which is co-expressed with the NICD transgene after cre-recom-
binase-mediated activation of transcription. As shown in Fig-
ure S1B, only the liver expressed detectable amounts of GFP,
while in all other tested organs the transgene was not activated.
To ensure expression and activity of the intracellular domain of
Notch in cholangiocytes and hepatocytes, we performed immu-
nostainings on mouse liver tissue from NotchIC::AlbCre mice
and wild-type controls, using antibodies specific for the cleaved
form of Notch. As shown in Figure 1D, NICD expression was
detected in both cell types in the transgenic animals but not in
wild-type liver controls. In line with a constitutive activation of
Notch signaling, we also detected strong expression of HES1,
a transcriptional target of the Notch pathway in Notch IC::AlbCre
livers (Figure 1D) and in liver lysates (Figure 1E).
Given the expression of Notch ICD in hepatocytes and the
biliary compartments of the liver, we first set out to analyze the
functional consequences of Notch expression in hepatocytes.
Upon histologic examination of theNotchIC::AlbCre liver tissues,
we detected a significant increase in the cell size of the NICD-
positive hepatocytes as well as variations in nuclear size in trans-
genic livers compared to wild-type controls (Figure 2A). Serum
transaminases and different liver metabolites were also changed
in NotchIC::AlbCre mice compared to wild-type controls (Fig-
ure S1C). To measure the size of individual hepatocytes, we
stained liver sections with a specific antibody against beta
catenin (Kossatz et al., 2004) and quantified the differences
between NotchIC::AlbCre and wild-type controls (Figures 2A
and 2B). In accordance with an increase in cell size, we also
noticed a reduction in the number of hepatocytes per visual field
in the NotchIC::AlbCre compared to wild-type livers (Figure 2C).
Because an increase in hepatocyte size can be the result of a
change in the nuclear-to-cytoplasmic ratio, we determined
nuclear sizes and DNA content in NotchIC::AlbCre mice and
wild-type control mice. As shown in Figure 2A, the nuclei of
hepatocytes in NotchIC::AlbCre mice are significantly larger
than those in control mice. To analyze if these changes were
paralleled by an increase in the amount of nuclear DNA, we
performed Feulgen staining and measured the DNA content of
single nuclei by cytometry. As shown in Figure 2D, we found
that the nuclei of hepatocytes in the NotchIC::AlbCre mice are
not only enlarged but also contain significantly more DNA than
the nuclei of nontransgenic control livers. Nuclear enlargement
and an increase in DNA content are often the result of endoredu-
plication cycles in which the cell undergoes continuous rounds of
DNA replication without cytokinesis (Kossatz et al., 2004). To test
whether the NotchIC::AlbCre livers also display alterations with
regard to cellular proliferation, we performed partial (two-thirds)
hepatectomies in NotchIC::AlbCre transgenic animals and
compared their regenerative potential with that of wild-type
organs. As shown in Figure 2E, expression of NotchIC::AlbCre
leads to an almost complete loss of regeneration potential insix mice per time point were counted. The average number of HH3-positive cells
NotchIC::AlbCre mice is displayed relative to the number of HH3-positive cells in
(G) Analysis of the expression levels of cyclin A, cyclin E, p27, and actin in liver tiss
indicated mouse strains at the age of 10 weeks.
Scale bars represent mean values ± SEM. *p < 0.05; **p < 0.001.transgenic livers of 10-week-old mice as shown by a reduction
of BrdU uptake after partial hepatectomy and a concomitant
reduction in cells entering mitosis as measured by histone H3
phosphorylation (Figure 2F). This lack of proliferation was
accompanied by a significant increase in hepatocyte cell size
and a reduction in cell number after partial hepatectomy, thereby
indicating that the NotchIC::AlbCre mice regenerated their liver
mass through cellular hypertrophy of the remaining hepatocytes
(Figure S1D). At themolecular level we found that wild-type livers
downregulate the cyclin kinase inhibitor p27kip1 and started to
express S phase cyclins E and A after induction of cell cycle pro-
gression by partial hepatectomy (Figure 2G). Importantly and in
contrast to wild-type livers, we detected elevated levels of cyclin
E and cyclin A even before partial hepatectomies were per-
formed in NotchIC::AlbCre expressing livers. Together these
results suggest that the expression of the intracellular domain
of Notch in hepatocytes results in the induction of endoredupli-
cation cycles and a severe impairment of cellular proliferation.
Expression of Notch ICD in Mouse Livers Leads to the
Formation of Progenitor Cell Derived Cholangiocellular
Carcinomas
To understand the long-term consequences of NICD overex-
pression, we followed a cohort of mice for up to 15 months. In
7-month-old mouse livers, we observed areas with clusters of
small cells with an epithelial appearance (Figure 3A) that also
formed gland-like structures. To determine the origin of these
cells, we stained liver sections with antibodies specific for the
biliary tract (CK7, CK17, and CK19), hepatocytic markers
(CK8/18), and the stem cell marker CD34. As shown in Figure 3A,
the small epithelial cells stained positive for biliary-hepatocytic
as well as stem cell markers, a finding which is typical for cells
that show characteristics of hepatocytic and cholangiocytic dif-
ferentiation. Such cells often arise through the transformation of
bipotential hepatic progenitor cells (Kim et al., 2004), which are
located in the canals of Hering.
Importantly, as early as 8 months after birth we started to
observe changes in nuclear morphology in primary liver tissues
from NotchIC::AlbCre mice. To test whether the observed cells
were indeed tumor cells, we transplanted primary tissue from
NotchIC::AlbCre mouse livers subcutaneously on the flanks of
immunodeficient mice. All implantations resulted in the formation
of tumors. Figure 3B shows the growth curve of the subcutane-
ous tumors that arose after cell transplantation. Histopathologic
analysis revealed that these tumors show many features of
human CCCs (Figure 3C), including the expression of CK7 and
CK17 and a typical desmoid reaction of the surrounding tissue.
Liver tissue from Alb-Cre mice was used as a control and did
not give rise to tumors (Figure S2G). These results suggested
that intrahepatic expression of NICD in hepatic progenitor cells
can induce differentiation of these cells toward the biliary lineage
and that, over time, NICD expression induces malignant trans-
formation of these cells. To directly test this hypothesis, wein the wild-type mouse was set as 100%. The number of HH3-positive cells in
the wild-type mice.
ue lysates at the indicated time points after induction of liver regeneration in the
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Figure 3. Expression of Notch ICD in Mouse Liver Leads to Formation of Progenitor Cell Derived Cholangiocellular Carcinomas
(A) H&E stained liver sections of NICD:AlbCremice. Immunohistochemical staining of NotchIC::AlbCre livers at the age of nine months using antibodies against
CK7, CK19, CK17, CK8-18, CD34, and CD34/Cytokeratin double staining.
(B) NotchIC::Alb Cre livers at the age of 9 months were minced and injected subcutaneously into nude mice. The growth of the resulting tumors was monitored.
(C) H&E and immunohistochemical analysis of the explanted tumor tissue using CK7 and CK17 antibodies 3 weeks after implantation of tumor cells.
(D) Growth curves of tumors after s.c. injection of progenitor cells of the indicated genotypes: progenitor cells expressing c-Myc and Akt, progenitor cells
expressing the intracellular domain of notch and a control shRNA (ICN-shCtrl.), progenitor cells expressing ICN together with a shRNA targeting cyclin E (ICN-
shCyc.E), progenitors that only express shRNA control (shCtrl.), and progenitor cells expressing only shRNAs that target cyclin E (shCyc.E-A/B).
(E)H&Estainedtissuederived fromsubcutaneouslygrowing tumors thatoriginated fromNICDexpressingbipotentialprogenitorseither transducedwith ICN (ICN)and
a shRNA control (ICN-shCtrl) or with Myc/Akt. The circle indicates atypical fused glands with hyperchromatic and irregular nuclei growing in a desmoplastic stroma.
See also Figure S2.
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Notch Induces Cholangiocellular Carcinomainfected previously described mouse bipotential liver progenitor
cells (Zender et al., 2006) with retroviral vectors to stably overex-
press the intracellular domain of Notch. Vector-infected cells
served as controls. Figure S2A shows the expression levels of
NICD in such cells compared to empty vector-infected cells.
Cells stably expressing NICD were subcutaneously injected
into nude mice and tumor growth was analyzed over time. While
control vector-transduced cells did not give rise to tumors,
NICD-overexpressing cells formed subcutaneous tumors (Fig-
ure 3D) in all transplantation experiments. These tumors
showed all features of CCCs (Figure 3E). Interestingly, tumors
arising from progenitor cells stably transduced with c-Myc and
a constitutive active form of Akt showed a different histopathol-
ogy and were classified as undifferentiated hepatocellular carci-
nomas/hepatoblastomas (Figure 3E). These results indicate that
expression of the intracellular domain of Notch leads to tumor
formation in all transgenic mice and can transform hepatic pro-
genitor cells thereby leading to the development of CCCs.
Notch Signaling Leads to Dysregulated Expression
of Cyclin E and Genetic Instability
To understand the molecular pathogenesis of Notch-dependent
CCC formation, we focused our analysis on the function of the
cyclin E protein. As shown in Figure 2G, cyclin E is highly ex-
pressed in NotchIC::AlbCre-derived liver tissue even before the
onset of liver regeneration (time point 0). In line with this finding,
we detected high levels of cyclin E protein within the CCCs
derived from NotchIC::AlbCremice (Figure 4A). Previous studies
on the oncogenic function of cyclin E suggested that cyclin E in-
duces DNA damage, thus resulting in genetic instability and
contributing to the formation of malignant tumors (Spruck
et al., 1999). We therefore tested if cyclin E-overexpressing chol-
angiocellular tumors might show signs of DNA damage by stain-
ing primary mouse CCC tissues derived from NotchIC::AlbCre
mice with antibodies specific for the phosphorylated form of
Ser-139 of histone H2AX (gH2AX), a marker for DNA double-
strand breaks. As shown in Figure 4B, we found that more
than 70% of all cells in these CCCs show signs of DNA damage
as compared to wild-type liver tissue. Similarly, tumor tissues
derived from nude mice transplanted with primary tumor cells
fromNotchIC::AlbCre also showed high levels of cyclin E expres-
sion and stained positive for gH2AX (Figure 4C). Mice expressing
only cre-recombinase do not show any signs of genetic insta-
bility as measured by gH2AX staining (Kossatz et al., 2010).
We then determined whether a reduction in cyclin E expression
would reduce the number of gH2AX-positive cells. Figure 4D
shows that transfection of human MzChA1 cholangiocarcinoma
cells with siRNAs against cyclins E1 and E2 (Figure S2B) led to a
significant reduction in the number of gH2AX-positive cells.
Based on these results, we speculated that Notch signaling
might be directly involved in the regulation of the cyclin E pro-
moter and thus in the induction of genetic instability and CCC
initiation and progression. Interestingly, the cyclin E1 promoter
contains several Rbpjk binding sites that could be involved in
the regulation of the promoter by NICD signaling. We used a pre-
viously described cyclin E1 promoter luciferase reporter
construct (Geng et al., 1996) to measure promoter activity in
the CCC cell with or without NICD overexpression. To determine
the activity of the cyclin E gene, we transfected the CycE-Lucpromoter construct into CCC cells (MzChA1, TFK1) and
measured luciferase expression in these cells as compared to
that in hepatocellular carcinoma cell lines (Hep3B, HepG2). As
shown in Figure 4E, we found higher basal levels of cyclin E pro-
moter activity in the CCC cell lines as compared to levels in liver
cancer cells (Hep3B) or hepatoblastoma cells (HepG2). Next, we
determined whether NICD was able to induce the activation of
the cyclin E promoter. Cotransfection of NICD with the CycE-
Luc reporter construct resulted in a more than 10-fold induction
of the cyclin E promoter (Figure 4E). Moreover, cotransfection of
NICD with an expression plasmid for the dominant-negative
co-activator Mastermind prevented the activation of the cyclin
E promoter by NICD, indicating that the activation of the cyclin
E promoter was a direct consequence of NICD activity.
Given the importance of cyclin E expression for the generation
of genetically unstable CCC cells, we next tested whether the
induction of cyclin E is required for the observed oncogenic
transformation of bipotential hepatic progenitors. For this
purpose, we transduced NICD-expressing liver progenitor cells
with retroviruses for stable expression of two different shRNAs
against cyclin E. After selection, we measured the knockdown
level of cyclin E in these cell populations (Figures S2C and S2D)
and transplanted these cells subcutaneously into immunodefi-
cient mice. As shown in Figure 3D, compared to ICN-expressing
cells that were transduced with control shRNAs, there was a
strong inhibition of tumor development from cells with stable
expression of cyclin E shRNAs together with ICN. Overall, only
one mice developed tumors (mouse 1a,1b). Western blot anal-
ysis of the tumor tissue showedprofound cyclin E protein expres-
sion (Figure S2E), indicating a selection against RNAi-mediated
cyclin E knockdown in these particular tumors. Our results sug-
gest that expression of NICD results in the activation of the cyclin
E promoter and increased cyclin E expressionwhich, through the
induction of genetic instability, leads to the formation of CCCs.
Notch 1 and 3 Are Overexpressed in Human
Cholangiocellular Carcinoma
Prompted by these results, we next tested whether the Notch
pathway is also active in human CCC cells and tissues. We first
determined the expression and activity of the Notch signaling
pathway in three established human CCC cell lines (TFK1,
MzChA1, and EgI1) and also in a primary cell line that we derived
from a CCC tumor specimen (SZ1). As shown in Figure 5A, all
CCC cell lines expressed the Notch1 receptor as well as the
Notch ligand jagged while hepatocellular or colon carcinoma
cell lines did not show an activation of this pathway (Figure S2F).
To determine whether the Notch signaling pathway is active in
CCC cells, we used an antibody that recognizes the cleaved
form of Notch 1 (Notch val 1744) and the downstream target
gene Hes1. As shown in Figure 5A, all CCC cell lines expressed
the activated form of the Notch receptor and the HES1 protein,
indicating that the Notch signaling pathway is active in these
tumor cells but not in HeLa cells, which we used as a control.
To ensure that the NICD transgenic mouse line is an adequate
model system, we compared the expression levels of NICD in
the CCCs that arose in our transgenic animals to the levels ex-
pressed in the human CCC cell lines. As shown in Figure 5B,
mouse tissue and human CCC lines express comparable levels
of cleaved Notch and HES1 protein. Finally, we tested whetherCancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc. 789
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Figure 4. Notch Signaling Leads to the Transformation of Bipotential Hepatic Progenitors through Dysregulation of Cyclin E Expression
(A) Immunohistochemical staining of wild-type and NotchIC::AlbCre livers at the age of 9 months using a cyclin E antibody.
(B) Livers from wild-type controls or tumor tissue derived from 9-month-old NotchIC::AlbCremice were stained with a gH2AX antibody to determine the number
of nuclei that showed signs of DNA damage. The plot shows the staining results of at least 300 cells per mouse strain. An example of NotchIC::AlbCre and wild-
type nuclei is shown in a 4003 magnification on the right side.
(C) Representative examples of gH2AX and cyclin E stained transplanted mouse CCCs and wild-type liver control.
(D) Statistical analysis of gH2AX foci in MzChA1 cells and after depletion of cyclin E expression through siRNA-mediated knockdown of cyclin E1, cyclin E2,
or both.
(E) MzChA1, TFK1, Hep3B, and HepG2 cells were transfected with the indicated plasmids and relative luciferase activity was measured after 48 hr. Scale bars
represent mean values ± SEM. *p < 0.05; **p < 0.001.
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Notch Induces Cholangiocellular Carcinomathe activation of the Notch pathway is involved in the pathogen-
esis of human CCC. We determined the expression levels of the
Notch receptors (Notch 1, 2, 3, and 4) in 56 primary CCC tumor
tissues (see Table S1 for details) with immunohistochemical
staining. As shown in Figure 5C and in the diagram in Figure 5D,
we found that the majority of all CCCs overexpress the Notch 1
receptor. Additionally, we found a strong overexpression of the790 Cancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc.Notch 3 receptor in primary tumor tissue as compared to that in
wild-type liver tissue. For both types of receptors, we detected
a predominant nuclear staining, whereas normal liver tissue did
not stain positive for either receptor (Figures S3A and S3B).
Finally, we tested the expression of the cyclin E protein in our
collection of primary human CCC tissues. As shown in Figures
5E and S3C, we found a strong or very strong expression of the
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Activated in Human CCC
(A) TFK1, MzChA1, EGI1 cells, a CCC primary
culture (SZ1), and HeLa cells were lysed and the
expression levels of Notch 1, cleaved Notch,
Jagged 1 and HES1 were analyzed by western
blotting.
(B) Comparison of cleaved Notch and HES1 levels
in human CCC cell lines and tumor tissue derived
from NotchIC::AlbCre mice. Actin and GAPDH
were used as loading controls.
(C) Fifty-six different human CCCs were screened
for Notch 1, 2, 3, or 4 expression using a tissue
microarray.
(D) Analysis of the staining intensities of the tissue
microarray displayed is the percentage of tumors
that express the Notch receptors 1–4 in the cyto-
plasm as well as in the nucleus in the 56 CCC
samples tested.
(E) Immunohistochemical analysis of 56 human
CCCs shows a strong expression of cyclin E1
compared to wild-type livers.
See also Figure S3 and Table S1.
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Because our analysis of the cyclin E promoter suggested that
cyclin E is a transcriptional target of Notch signaling, we tested
whether Notch and cyclin E expression correlate in primary
CCC tissues. Using the Kendall tau-b rank test, we found that
cyclin E1 and Notch 1 showed a highly significant (p < 0.001)
co-expression in the CCC tissues tested. These results suggest
that overexpression of Notch promotes the expression of the
cyclin E gene through activation of the cyclin E promoter, which
results in the formation of DNA double-strand breaks in human
CCC cells.
Notch Signaling as a Therapeutic Target in CCC
Our analysis of primary CCC tissues and the observation that
NICD transgenic mice develop CCCs point toward a central
role of the Notch signaling pathway in the formation of these
tumors. To test whether the expression of Notch was also
required for CCC maintenance, we transfected the cells with
siRNAs specific for Notch 1. As shown in Figure 6A, loss of Notch
1 expression led to a reduction in HES1 and cyclin E expression
while p53, p27, and p21were strongly induced. Forty-eight hoursCancer Cell 23, 784–7after the transfection of Notch 1 siRNA,
approximately 50% of all MzChA1 cells
had undergone apoptosis (Figure 6B).
Combined ablation of Notch 1 and 3 by
siRNA led to an even more pronounced
effect, indicating that signaling through
both receptors is required for CCC main-
tenance (Figures S4A and S4B).
Notch signaling depends on g-secre-
tase-mediated generation of NICD, which
translocates to the nucleus to induce a
cell type-specific transcriptional pro-
gram. To test whether g-secretase inhibi-
tion of Notch signaling might constitute a
treatment option against CCC,we treatedthese cells with the g-secretase inhibitor N-[N-(3,5-difluoro-
phenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). As
shown in Figure 6C, DAPT treatment resulted in a time-depen-
dent decrease in the expression of the cleaved form of the Notch
receptor and theNotch target geneHes1. Similar resultswere ob-
tained with other CCC cell lines (Figure S4C). In line with our
observation that Notch controls cyclin E transcription, DAPT
treatment also led to adecrease in cyclin Eexpression inMzChA1
cells as determined by RT-PCR (Figure S4D). To determine the
functional consequences of Notch inhibition, we determined
the number of apoptotic MzChA1 cells after treatment with
DAPT. As shown in Figure 6D, DAPT treatment of MzChA1 cells
resulted in a significant increase in the number of apoptotic cells
asmeasuredby the activation of caspases 3and7. This decrease
in viability was accompanied by a significant reduction of BrdU
uptake (FigureS4E) and a strong increase in the expression levels
of the cyclin kinase inhibitors p21 and p27 as well as the tumor
suppressor protein p53 (Figure S4F). Similar results were found
in the other CCC lines (EGI-1, TFK-1) (data not shown).
Finally, we tested whether inhibition of Notch signaling would
also affect the growth of xenotransplanted human CCCs. To this95, June 10, 2013 ª2013 Elsevier Inc. 791
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Figure 6. Notch Signaling as a Therapeutic
Target in CCC
(A) Western blot expression analysis of Notch 1,
HES1, cyclin E, p21, p53, and p27 after siRNA-
mediated knockdown of Notch 1 in MzChA1 cells.
(B) Determination of cell death (sub G1 fraction) by
FACS scan analysis in MzChA1 cells in which
Notch1 expression was reduced through siRNA-
mediated knockdown.
(C) MzChA1 cells were treated with DAPT (10 mM)
for the indicated periods of time. At different time
points cells were lysed and the expression levels of
Notch 1, cleavedNotch 1, andHES1were analyzed
by western blotting.
(D) Caspase 3/7 activity in DAPT-treated MzChA1
cells at the indicated time points. The y-axis de-
scribes the relative caspase activity in percentages
as compared to the DMSO control treated cells.
(E) Primary human CCC cells (SZ1) were trans-
planted under the skin of nu/nu mice (ten mice for
each group). When the tumors reached a size of
approximately 150–200 mm3, mice were treated
with DAPT at a concentration of 50 mg/kg every
72 hr or with DMSO, which was used to dissolve
DAPT (control).
(F) Western blot analysis of the expression levels of
cyclin E1, p21, p27, p53, and actin in tumor tissue
lysates fromDAPT treated or untreatedmice. Scale
bars represent mean values ± SEM.
See also Figure S4.
Cancer Cell
Notch Induces Cholangiocellular Carcinomaend, we established primary CCC cell lines from human CCCs
that were resected at our institution. Cells derived from cell line
SZ1 were mixed with Matrigel and injected subcutaneously
into immunodeficient mice. When the tumors reached a size of
approximately 150–200 mm3, mice were treated with DAPT at
a concentration of 50 mg/kg every 72 hr. As shown in Figure 6E
and Figure S4G, inhibition of g-secretase resulted in a significant
inhibition of tumor growth as compared to untreated controls.
This inhibition of tumor growth was accompanied by the induc-
tion of p21, p27, and p53 and a downregulation of cyclin E
expression in the primary tumor tissues (Figure 6F). Histologic
examination of these tumors revealed, in accordance with the
results we had obtained using CCC cell lines, that treatment
with DAPT resulted in the induction of apoptosis in the xeno-
transplanted tumors as shown by TUNEL staining of the primary
tissues (Figure S4H).
DISCUSSION
The pathogenesis of CCC is only incompletely understood. A
number of genetic and epigenetic changes as well as alterations792 Cancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc.in growth factor signaling have been
described. Nevertheless, treatment op-
tions are still sparse and given the lack of
a detailed understanding of the underlying
pathogenesis, targeted therapies are diffi-
cult to implement. In this study, we used a
transgenic mouse line that expresses the
intracellular domain of the Notch 1 recep-
tor in liver cells starting at day 9.5.Our phenotypic andmolecular analysis of theNotchIC::AlbCre
mice revealed opposite roles for Notch signaling in the hepatic
and cholangiocytic compartments. We found that NICD-overex-
pressing hepatocytes undergo endoreduplication cycles that
result in the formation of polyploid liver cells. This defect in
mitotic cell division is also apparent in liver regeneration experi-
ments that show that NICD-expressing hepatocytes fail to re-
enter the cell cycle after a partial hepatectomy. In line with our
findings Croquelois and colleagues showed that loss of Notch
1 in hepatocytes led to the overproliferation of hepatocytes,
which caused the formation of regenerative nodules (Croquelois
et al., 2005). Together, these results suggest that Notch signaling
in hepatocytes is primarily antiproliferative and prevents uncon-
trolled proliferation of liver cells.
We found that overexpression of NICD results in the formation
of CCCs, implicating this signaling pathway in the pathogenesis
of this tumor. Zong and colleagues convincingly showed that
ectopic Notch expression led to the formation of biliary epithelial
cells in the hepatic lobule (Zong et al., 2009). Moreover, expres-
sion of Notch in livers of 6-day-old mice led to the formation of
ectopic biliary structures within the liver. Their experiments
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decision in hepatoblasts or even terminally differentiated hepa-
tocytes that allows them to differentiate toward the biliary
lineage. The ability of hepatocytes to change their fate decision
under the influence of AKT and Notch signaling or under condi-
tions of chemically induced carcinogenesis has been shown
recently (Fan et al., 2012; Sekiya and Suzuki, 2012). These
studies provided evidence that hepatocytes localized around
the central vein can be transformed into biliary cancers. While
a growing body of evidence supports the hypothesis that human
CCC is derived from intrahepatic stem cell compartments
(Cardinale et al., 2012; Nakanuma et al., 2010), it needs to be
shownwhether a change in cellular differentiation can contribute
to human CCC pathogenesis. Recent data in other systems indi-
cate that Notch signaling drives intestinal cell fate determination
of progenitor cells, for example, those lining the intestinal crypts,
and blockade of Notch signaling via gamma secretase inhibition
forces intestinal progenitor cells to differentiate into goblet cells
(van Es et al., 2005; Zecchini et al., 2005). This pathologic profile
is reminiscent of that seen inHes-1 deficientmice, a downstream
Notch target gene (Kodama et al., 2004). Our analysis showed
that expression of NICD in mouse liver cells results in the forma-
tion of CCCs, which in addition to cholangiocytic features, also
express surface markers associated with stem cells thereby
indicating that NICD expression in undifferentiated liver progen-
itor cells might have transformed those cells into tumor cells. It is
not known how the expression of Notch ICD in differentiated
cholangiocytes may also result in the formation of cancers.
The finding that NICD expression in hepatic progenitors
results in the formation of CCCs was further substantiated by
the fact that cells isolated from these primary tumors led to the
formation of CCC after transplantation into nude mice. Given
the high plasticity of these cells, we cannot exclude that Notch
signaling might lead to the formation of tumors that resemble
features of hepatocellular carcinoma or even mixed phenotypes
(Villanueva et al., 2012). We therefore set out to directly prove
that aberrant Notch signaling in bipotential liver progenitor cells
causes the formation of CCC. To this end, we created progenitor
cell lines that stably express NICD and found that these cells did
indeed start to form tumors that show all characteristics of CCCs
after transplantation into mice. These tumors also showed
elevated levels of cyclin E expression and a high degree of
genetic instability. We therefore concluded that liver progenitor
cells can act as the cells of origin in the formation of CCCs in
response to Notch signaling.
A central question that arose out of these findings is how the
expression of NICD can lead to the formation of CCC. In this
work, we found that cyclin E protein levels are greatly increased
not only in CCCs derived from NotchIC::AlbCre mice, but also
in primary human CCC tissues. Several mouse models have
demonstrated that deregulated cyclin E expression is causally
associated with tumorigenesis in vivo. Overexpression of human
cyclin E in mammary or thymic tissues, or prevention of cyclin E
degradation throughmutation of the T380 phosphorylation site in
mouse cyclin E, resulted in the formation of tumors (Hwang and
Clurman, 2005; Loeb et al., 2005). The oncogenic function of
cyclin E is coupled to its ability to induce double-strand breaks
that ultimately result in the formation of genetically unstable
cells. Using gH2AX as a marker for double-strand breaks, weshowed that the tumors derived from NotchIC::AlbCre mice as
well as tumors derived from NICD-expressing bipotential pro-
genitors show high levels of DNA double-strand breaks and
that reduction of cyclin E expression ameliorates this phenotype.
Interestingly the dysregulation of cyclin E expression is caused
by an increased transcription of the cyclin E promoter in
response to NICD expression a finding that defines cyclin E as
a direct transcriptional target of the Notch signaling pathway.
Given that suppression of cyclin E expression by shRNA treat-
ment results in a complete suppression of tumor formation in
NICD-expressing liver progenitors, we conclude that cyclin E is
indeed a critical downstream effector of Notch signaling-
induced tumor formation.
Our observations together with the data provided by Zong and
Stanger therefore suggest that Notch signaling can induce a
biliary differentiation program in hepatocytes or hepatic progen-
itor cells, which together with the aberrant expression of the
cyclin E protein results in the formation of intrahepatic CCCs. It
is currently unknown why the Notch 1 and 3 receptors are upre-
gulated in CCC cells. T cell acute lymphoblastic leukemia, breast
cancer, and other tumors or cell lines derived from such cancers
show genetic alterations that affect the expression of different
components of the Notch signaling pathway (Koch and Radtke,
2007).
Recently, Fbw7, the F-Box protein that controls the turnover of
Notch 1 as part of a SCFFbw7 ubiquitin ligase, was shown to be
mutated in up to 35% of all CCCs examined (Akhoondi et al.,
2007). This result points to a defect in Notch turnover that might
contribute to the increase in protein levels. Interestingly the
SCFFbw7 complex also ubiquitylates the cyclin E1 and E2 pro-
teins and loss or mutation of the Fbw7 protein results in
increased cyclin E expression (Koepp et al., 2001; Welcker
et al., 2003). We have shown that overexpression of the Notch
ICD in mouse livers leads to an increase in cyclin E expression
and that Notch ICD can directly transactivate the cyclin E1 pro-
moter. Loss of Fbw7 might therefore cause an increase in cyclin
E levels not only through a reduction of cyclin E ubiquitylation
and turnover, but also through an increased transcription of
the Cyclin E gene through the Notch signaling pathway.
CCCs frequently arise under conditions of chronic inflamma-
tion. The interleukin-6 (IL-6)/gp130 signaling system constitutes
an important component of the inflammatory response in the
liver and was shown to be involved in the pathogenesis of
CCCs. This aberrant overexpression of IL-6 is a consequence
of the epigenetic silencing of the suppressor of cytokine
signaling 3 (SOCS-3) (Isomoto et al., 2007). Intriguingly IL-6 is
able to induce a Notch-3–dependent transcriptional activation
of the jagged gene in breast cancer cells (Sansone et al.,
2007). Dysregulation of Notch signaling might therefore be a
result of alterations in its proteolytic turnover and exogenous
factors like the stimulation of jagged transcription by IL-6. While
this hypothesis awaits experimental proof, our experiments
using isolated NICD-expressing progenitors show that transfor-
mation of these cells does not require additional inflammation.
To date, no specific treatment exists for patients with CCCs
that are not eligible for surgery. We therefore set out to test
whether inhibition of Notch signaling would interfere with the
proliferation and survival of CCC cells. Loss of Notch signaling
either by inhibition of g-secretase or by suppressing NotchCancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc. 793
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expression resulted in the induction of cell cycle arrest and
apoptosis. Notch inhibition also led to the regression of estab-
lished xenotransplant tumors derived from CCC cell lines in vivo.
Inhibition of g-secretase activity might therefore constitute a
molecular target that interferes with the dysregulated expression
of cyclin E.
In this study we found that NotchIC::AlbCre mice not only
formed ectopic biliary structures, but also intrahepatic CCCs.
Together with the observation that Notch can induce a biliary
cell fate in bipotential progenitors lead to the idea that the path-
ogenesis of intrahepatic CCCs might differ significantly from the
formation of biliary tumors that arise primarily from the bile ducts
(i.e., Klatskin carcinoma). Our data suggest that intrahepatic
CCC might constitute a tumor that forms as a result of aberrant
Notch signaling in hepatic progenitors that transform into tumor
cells. Moreover we show that inhibition of Notch signaling consti-
tutes an attractive target for future clinical trials in patients with
intrahepatic CCCs.
EXPERIMENTAL PROCEDURES
Animals and Partial Hepatectomy Procedures
ROSA26 NICD mice (Murtaugh et al., 2003) were crossed with AlbCre mice
(Kellendonk et al., 2000) to generate mice with a liver-specific overexpression
of the activated form of the Notch 1 receptor. All genotyping was performed as
described (Murtaugh et al., 2003). In all experiments, 8- to 10-week-old wild-
type and double transgenic littermates were used. Mice were killed at the
indicated time points after surgery, and the number of mice analyzed ranged
from five to six per time point. Partial hepatectomy was performed as
described (Satyanarayana et al., 2003). All animal experiments were per-
formed after review and approval by the Niedersa¨chsische Landesamt fu¨r
Verbraucherschutz und Lebensmittelsicherheit, Lower Saxony, Germany.
Immunohistochemical Staining of Mouse and Human Tissues
Immunohistochemical staining of mouse and human tissue was performed as
described previously (Kossatz et al., 2004). Surgical specimens were taken for
diagnostic and scientific purposes permitted by the Ethics Committee of the
University of Bern, Switzerland. Informed consent was obtained from all
patients.
Feulgen Staining
To determine the DNA content, 3 mm sections were Feulgen-stained using the
Feulgen Staining Kit (Merck). Ploidy analysis was performed with the Ahrens
ICM, Cytometric System. Statistical analysis was done using the Dunnett
t test (DNA ploidy) and the mixed models analysis of variance (nuclear size
analysis).
RT-PCR
RNA extraction was done as described (Satyanarayana et al., 2003). For cDNA
synthesis, 2 mg of RNA were used. The RT reaction was carried out using
SuperScript-II RNase H reverse transcriptase (Invitrogen). For semiquantitive
RT-PCR, 1 ml cDNA was amplified using the following cycles: denaturation
94C for 30 s, annealing 57C for 1 min, and extension 72C for 45 s using
RedTaq (Sigma) for 35 cycles. Actin was used as a control.
siRNA
siRNA knockdownwas performed using FuGene6 transfection reagent. Trans-
fectionswere performed using siRNA at a concentration of 20 nM for Notch 1 si
RNA; sc-36095 and Notch 3 siRNA; sc-37135 from Santa Cruz. siRNA in a
concentration of 40 nM was used for cyclin E1 and cyclin E2 knockdown.
DAPT Treatment In Vitro
Five milligrams of DAPT were dissolved in 1 ml dimethyl sulfoxide. Cells were
plated in six-well plates. When the cells reached 60% confluency, they were794 Cancer Cell 23, 784–795, June 10, 2013 ª2013 Elsevier Inc.treated with 38.7 mM DAPT. Cells were collected after 12, 24, 36, and 48 hr
for protein extraction and analyzed by western blot.
Western Blot
Antibodies included cleaved Notch 1 (Val1744, Cell signaling); Hes-1 (Santa
Cruz Biotechnology); Notch 1: C-20; sc 6014 (Santa Cruz), Notch 3: (M-134);
sc5593 (Santa Cruz); Jagged 1:C-20, sc-6011 (Santa Cruz); p27: Cat 610242
(BD Transduction), p21 C-19; sc397 (Santa Cruz), p53 FL-393, sc6243 (Santa
Cruz); and cyclin E: C19 (Delta Biolabs). Western blots were performed as
described (Malek et al., 2001).
Generation of Immortalized Bipotential Liver Progenitor Cells,
Retroviral Transduction, and Subcutaneous Injection of Cells
Bipotential liver progenitor cells were isolated from C57Bl6 embryonic mouse
livers as described recently (Zender et al., 2006). For additional information,
please refer to the Supplemental Experimental Procedures.
Statistical Analysis
Statistical analysis was carried out using Microsoft Excel software. Unless
stated otherwise, all data are presented as mean ± SD; error bars represent
SD in all figures. Intergroup comparisons were performed by two-tailed
Student’s t test. A p value <0.05 was considered to be statistically significant.
Caspase 3/7 Assay and TUNEL Staining
For detection of apoptosis, we used theCaspase-Glo 3/7 Assay fromPromega
that measures caspase-3 and -7 activities because these members of the
caspase family play important roles in apoptosis in mammalian cells. Themea-
surements were done as described in the manufacturer manual. We used the
In Situ Cell Death Detection Kit (Roche) according to the manufacturer’s
manual for TUNEL staining.
Luciferase Assay
MzChA1 cells were transiently transfected with a cyclin E promotor luciferase
reporter construct, a NICD expression construct, and phRL-TK (Promega) for
normalization using FUGENE. After 48 hr, luciferase activity was measured
using the ‘‘dual-luciferase reporter assay system’’ (Promega) following the
manufacturer’s instructions. In brief, cells were lysed in 13 passive lysis buffer;
after 10 min, cells were scraped off the dishes and incubated for 5 min on ice.
After centrifugation, 20 ml of cleared lysateswere used for analysis of luciferase
activity. The 96-well plate reader ‘‘Glomax-integrated luciferase technologies’’
(TURNER Biosystems) was used to quantify luciferase activity. Firefly lucif-
erase activity was normalized to cotransfected Renilla luciferase activity
(phRLTK).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2013.04.019.
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